Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection

February 21, 2024 8:00 AM

~ PF614-MPAR program receives FDA guidance ~SAN DIEGO, CA / ACCESSWIRE / February 21, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company applying transformative chemistry to improve prescription drug safety, is providing an update following its recent meeting with the Food and Drug Administration (FDA) regarding its second product, a ‘Next Generation' opioid analgesic with overdose protection,...

Read more

New U Hair(TM) Unveils Revolutionary TrichoBioScan(TM): Experts Calling It Key to Unlocking One’s Unique Hair Loss Mysteries

February 20, 2024 10:00 AM

A Scientific Personalized Approach Poised to Revolutionize How People Combat Hair LossTAMPA, FL / ACCESSWIRE / February 20, 2024 / New U Hair™, a national leading pioneer in preventative healthcare solutions since 2007, proudly announces the launch of its groundbreaking TrichoBioScan™. This state-of-the art diagnostic tool is set to redefine the approach to combatting hair loss at its root cause, offering individuals a chance to understand the...

Read more

Prolocor to Present New Clinical Evidence at ACC 24 Supporting the Use of PLATELET FCɣRIIA (PFCG) as a Key Tool in Individualizing Dual Antiplatelet Therapy (DAPT)

February 20, 2024 9:00 AM

Date April 6, 2024, Location Hall B4-5Abstract 1307-159 / 159ASSOCIATION BETWEEN PROGNOSTIC IMPLICATIONS OF PLATELET FCɣRIIA (PFCG) AND TREATMENT STRATEGY FOR MYOCARDIAL INFARCTIONPHILADELPHIA, PA / ACCESSWIRE / February 20, 2024 / Prolocor, Inc., a healthcare startup developing an innovative precision diagnostic test with the goal of predicting the risk of thrombosis by quantifying platelet FcγRIIa (pFCG test), today announced the acceptance of...

Read more

Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024

February 20, 2024 8:30 AM

IRVINE, CA / ACCESSWIRE / February 20, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that topline efficacy data from the VenoValve U.S. pivotal trial will be presented at the 2024 American Venous Forum (AVF) Annual Meeting being held March 3-6, 2024 in Tampa, Florida. The presentation will be made on Wednesday, March 6,...

Read more

Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG

February 20, 2024 8:10 AM

Ameluz ® transfer price to Biofrontera AG reduced significantlyControl of all US clinical trials of Ameluz transfers to Biofrontera Inc. on June 1WOBURN, MA / ACCESSWIRE / February 20, 2024 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company") , a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced the restructuring of agreements between the Company and its former parent company...

Read more

Biofrontera Inc. Announces Private Placement of Up To $16.0 Million Priced at Market per Nasdaq Rules

February 20, 2024 8:05 AM

Company secures financing of $8.0 million with an additional $8.0 million second tranche tied to milestones for aggregate proceeds of $16 million gross priced at market per Nasdaq rulesFunding and recent restructuring of supply agreement allow Biofrontera Inc to assume R&D activities and to support further commercial growthWOBURN, MA / ACCESSWIRE / February 20, 2024 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company") , a...

Read more

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

February 20, 2024 8:01 AM

Positive safety/tolerability profile achieved with TH104 showing self-resolving, mild side effect profile aligned with previous studiesPhase 1 clinical trial compared oral transmucosal delivery of TH104 to injectable reference approved drug completedCompany fully funded into 2025 with Phase 2 moderate-to-severe chronic pruritus in primary biliary cholangitis (PBC) study on-track and expected to initiate in 2024BRIDGEWATER, NJ / ACCESSWIRE /...

Read more

Invitation to Presentation of BioInvent’s Year-end Report 2023

February 20, 2024 4:30 AM

LUND, SE / ACCESSWIRE / February 20, 2024 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) invites investors, analysts, and the press to a presentation of the year-end report 2023 at 2:00 pm on February 22. The report will be published at 8:00 am CET the same day.BioInvent's CEO Martin Welschof will present the report together with CFO Stefan Ericsson. The presentation will be held in English.When: Thursday February 22, 2024,...

Read more

Hyris Technology Supports the Fight Against One of the World’s Deadliest Diseases, Malaria

February 20, 2024 3:00 AM

Hyris' molecular diagnostic technology has been adapted to enable real-time surveillance of mosquito vector insecticide resistance, which will aid in malaria control campaigns.LONDON, UK / ACCESSWIRE / February 20, 2024 / Hyris, working with an international team of researchers, has developed a prototype field-deployable surveillance system to detect insecticide-resistant malaria vector mosquitoes in the field without the need for transportation...

Read more

Enalare Therapeutics Announces Publication of a Clinical Study Demonstrating the Effect of ENA-001 on Improving Propofol-Induced Depression of the Hypoxic Ventilatory Response

February 15, 2024 8:00 AM

PRINCETON, NJ / ACCESSWIRE / February 15, 2024 / Enalare Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to developing novel compounds for the treatment of life-threatening critical care conditions and community health emergencies, today announced the publication of a respiratory depression study with its lead compound, ENA-001 in the journal Anesthesiology. The article entitled "Reversal of Propofol-induced Depression of...

Read more

Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

February 15, 2024 8:00 AM

KELOWNA, BC / ACCESSWIRE / February 15, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into definitive agreements for the purchase and sale of 1,558,443 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $2.31 per share (or per common stock equivalent in lieu thereof) in a...

Read more

Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider

February 14, 2024 9:15 AM

AI software expected to further enable Petros's efforts to make STENDRA the first ED product to be offered over the counterNEW YORK, NY / ACCESSWIRE / February 14, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces a new partnership with a leading, multi-billion-dollar AI software provider to adapt its technology for...

Read more

Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders

February 13, 2024 8:30 AM

Company Anticipates Reporting Complete Phase I Single Dose Results in AprilNEW YORK, NY / ACCESSWIRE / February 13, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, announced a step forward in its mission to address stress-related neuro-psychiatric disorders. The company has completed the first dose escalation step in the Phase I safety clinical trial for PT00114, its pioneering brain peptide compound. The...

Read more

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds

February 13, 2024 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / February 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 3,601,752 shares of common stock of the Company originally...

Read more

Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn’s and Colitis Organization (ECCO)

February 13, 2024 2:50 AM

PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that four scientific abstracts on its lead drug candidate, obefazimod for the treatment of...

Read more

Imagene Increases Accessibility of Rapid AI-Based Biomarker Profiling Through Integration With Sectra

February 12, 2024 9:00 AM

ImageneOI is the first NSCLC genomic profiling AI tool on the Sectra Amplifier Marketplace.TEL AVIV, ISRAEL / ACCESSWIRE / February 12, 2024 / Imagene, a pioneer in AI-based precision oncology, today announced the integration of its groundbreaking AI-based biomarker profiling platform, ImageneOITM, with international medical imaging IT company Sectra and their digital pathology solution. Healthcare providers around the world using the Sectra...

Read more

Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

February 9, 2024 4:15 PM

TORONTO, ON / ACCESSWIRE / February 9, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three months ended December 31, 2023 and provided an update on its business.During the first fiscal quarter, the company secured funding of up to C$23 million from the Canadian government toward the...

Read more

MRES: M2Biome 2023 Year-End Review and 2024 Looking Forward

February 9, 2024 9:30 AM

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / February 9, 2024 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to announce the following updates for its M2Biome division:The M2Biome division relates to...

Read more

Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan

February 9, 2024 2:20 AM

STOCKHOLM, SWEDEN / ACCESSWIRE / February 9, 2024 / Vicore Pharma Holding (STO:VICO)C21 is a potentially transformative therapy for the treatment of idiopathic pulmonary fibrosis (IPF)Vicore to receive USD 10 million upfront and is entitled to up to USD 275 million in milestones in addition to tiered royalty paymentsNippon Shinyaku has been granted exclusive rights to and will be responsible for development of C21 in JapanVicore retains rights...

Read more

BioInvent to Evaluate BI-1206 in Combination with Rituximab and Calquence

February 9, 2024 2:20 AM

LUND, SWEDEN / ACCESSWIRE / February 9, 2024 / BioInvent International (STO:BINV)Clinical supply agreement with AstraZeneca to support Phase 1/2a BI-1206 combination studyBI-1206 to be evaluated in combination with Calquence® and rituximab in Phase 1/2a trial in non-Hodgkin's lymphomaThe ongoing rituximab combination trial will be expanded to include the triplet armLund, Sweden - February 9, 2024 - BioInvent International AB ("BioInvent")...

Read more